EP3946378A1 - Sulfate de dextran dans les dermatoses inflammatoires - Google Patents

Sulfate de dextran dans les dermatoses inflammatoires

Info

Publication number
EP3946378A1
EP3946378A1 EP20714649.9A EP20714649A EP3946378A1 EP 3946378 A1 EP3946378 A1 EP 3946378A1 EP 20714649 A EP20714649 A EP 20714649A EP 3946378 A1 EP3946378 A1 EP 3946378A1
Authority
EP
European Patent Office
Prior art keywords
dermo
dextran sulfate
dermatologically
cosmetically acceptable
dextran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20714649.9A
Other languages
German (de)
English (en)
French (fr)
Inventor
Marie Françoise ARIES
Stéphane POIGNY
Hélène HERNANDEZ-PIGEON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Publication of EP3946378A1 publication Critical patent/EP3946378A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment

Definitions

  • Rosacea is a common chronic and progressive inflammatory dermatosis associated with vascular relaxation. It is a condition that affects the small vessels of the face. It frequently affects people with fair skin and can have significant psycho-emotional consequences.
  • the name of this pathology refers to the characteristic color that the face takes on during the disease.
  • Lichen planus is an itchy rash that only affects adults. This is an inflammatory skin condition of unknown origin. This dermatosis affects the skin, mucous membranes but also the hair and nails. These last two localizations are generally of chronic evolution and can leave irreversible consequences, such as alopecia and destruction of the nails. Prurigo is an intense itching of the skin with erythematous and vesicular papules with scratching lesions. It is most often an exaggerated sensitivity to insect bites, a sensitivity which lasts abnormally for a long time and which is frequent especially in young children.
  • Seborrheic dermatitis is a chronic inflammatory condition of the skin, which affects areas rich in sebaceous glands, namely the scalp and face. It is due to a yeast, Malassezia, present in the skin and which develops in the sebum. This condition evolves by outbreaks favored by stress, the absence of sun and pollution.
  • Acne is a common skin pathology, the result of inflammation of the pilosebaceous follicles due in large part to the colonization of Cutibacterium acnes in the infundibulum (Dréno et al., JEADV 2018, 32 (Suppl 2) 5-14 ).
  • Another subject of the invention relates to the use of dextran sulfate or a dermatologically or dermo-cosmetically acceptable salt thereof for the treatment and / or prevention of inflammatory dermatoses.
  • Dextran can be sulfated, especially in the presence of magnesium sulfate, to give dextran sulfate.
  • Dextran sulfate is therefore a dextran in which at least part of the hydroxyl groups has been replaced by sulfate groups.
  • the invention thus relates to dermatological or dermo-cosmetic compositions according to one of the embodiments of the present invention, characterized in that they are provided in a specific form suitable for topical application.
  • compositions generally contain, in addition to the dextran sulfate according to the present invention, a physiologically acceptable medium, generally based on water or on a solvent, for example alcohols, ethers or glycols. They can also contain surfactants, complexing agents, preservatives, stabilizers, emulsifiers, thickeners, gelling agents, humectants, emollients, trace elements, essential oils, perfumes, dyes, agents. mattifying agents, chemical or mineral filters, moisturizing agents or thermal waters, etc.
  • a physiologically acceptable medium generally based on water or on a solvent, for example alcohols, ethers or glycols. They can also contain surfactants, complexing agents, preservatives, stabilizers, emulsifiers, thickeners, gelling agents, humectants, emollients, trace elements, essential oils, perfumes, dyes, agents. mattifying agents, chemical or mineral filters, moisturizing agents or thermal waters, etc.
  • the keratinocyte is the most represented cell in the epidermis.
  • the epidermis releases various biologically active mediators, in particular bioactive lipids, prostaglandins and leukotrienes which play an important role in the initiation and modulation of inflammatory reactions in the skin but which also participate in the regulation of the immune response.
  • the keratinocyte appears to be a good model for pharmacological study of the skin. This cell model makes it possible to determine in vitro the capacities of various compounds to modulate the production of these mediators resulting from the metabolism of arachidonic acid.
  • RLU Relative Light Unit
  • Cont control
  • Conc concentration
  • Avg average
  • sem standard error to the mean
  • Inh inhibition
  • Stim stimulation by TNFa
  • Dexa dexamethasone
  • S Dex: dextran sulfate
  • NS not significant.
  • Stimulation with TNF ⁇ does induce activation of N FKB.
  • Dexamethasone used as an immunosuppressant inhibits this activation by more than 40% (P ⁇ 0.05 vs without TNFa), which makes it possible to validate the reliability of this test.
  • the dextran sulfate tested at 0.3 and 1 mg / ml does not make it possible to reduce the activation of N FKB.
  • dextran sulfate significantly (p ⁇ 0.01) reduced by 42% the activation of N FKB induced by TNF ⁇ .
  • atopic dermatitis is considered to be a complex disease involving several mechanisms.
  • the inventors have thus shown that normal human epidermal keratinocytes produced a significant amount of TSLP and IL-8 after 24 hours of stimulation with a cocktail of agents (Poly I: C, PamC3, IL-4 and IL-13) mimicking an environment of atopic dermatitis.
  • a cocktail of agents Poly I: C, PamC3, IL-4 and IL-13
  • the inventors demonstrate that the dextran sulfate according to the invention is very effective and is capable of preventing this release of inflammatory cytokines and in particular TSLP, a key marker in the development of atopic dermatitis, demonstrating a protective role in this. pathology.
  • the relative amount can be very high and variable depending on the experiments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
EP20714649.9A 2019-04-04 2020-04-03 Sulfate de dextran dans les dermatoses inflammatoires Withdrawn EP3946378A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1903628A FR3094637A1 (fr) 2019-04-04 2019-04-04 Sulfate de dextran dans les dermatoses inflammatoires
PCT/EP2020/059527 WO2020201492A1 (fr) 2019-04-04 2020-04-03 Sulfate de dextran dans les dermatoses inflammatoires

Publications (1)

Publication Number Publication Date
EP3946378A1 true EP3946378A1 (fr) 2022-02-09

Family

ID=67810765

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20714649.9A Withdrawn EP3946378A1 (fr) 2019-04-04 2020-04-03 Sulfate de dextran dans les dermatoses inflammatoires

Country Status (9)

Country Link
US (1) US20220175820A1 (ko)
EP (1) EP3946378A1 (ko)
JP (1) JP2022527851A (ko)
KR (1) KR20210148183A (ko)
CN (1) CN113766922A (ko)
CA (1) CA3135889A1 (ko)
FR (1) FR3094637A1 (ko)
MX (1) MX2021011999A (ko)
WO (1) WO2020201492A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113244162B (zh) * 2021-05-24 2022-08-02 杭州荔枝红生物科技有限公司 一种可溶性微针及其制备方法和在制备调节皮肤微生态产品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000178196A (ja) * 1998-12-11 2000-06-27 Seikagaku Kogyo Co Ltd 新規ヒアルロニダーゼ阻害剤及び外用剤
FR2799369B1 (fr) * 1999-10-08 2001-12-21 Oreal Association d'escine et de sulfate de dextran et son utilisation
FR2877565A1 (fr) * 2004-11-09 2006-05-12 Oreal Utilisation d'un sulfate de dextran de haut poids moleculaire comme agent apaisant
WO2008134430A1 (en) * 2007-04-24 2008-11-06 Novelmed Therapeutics Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
JP2013521300A (ja) * 2010-03-03 2013-06-10 ネオキュティス エスアー 抗菌ペプチド隔離化合物を用いた皮膚疾患および皮膚障害の処置のための組成物および方法

Also Published As

Publication number Publication date
US20220175820A1 (en) 2022-06-09
KR20210148183A (ko) 2021-12-07
CN113766922A (zh) 2021-12-07
JP2022527851A (ja) 2022-06-06
WO2020201492A1 (fr) 2020-10-08
CA3135889A1 (fr) 2020-10-08
MX2021011999A (es) 2021-11-17
FR3094637A1 (fr) 2020-10-09

Similar Documents

Publication Publication Date Title
EP1707189B2 (fr) Utilisation d'un produit d'huile de tournesol pour traiter la peau
EP1965808B1 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
US20180325969A1 (en) Cosmetic and pharmaceutical applications of lactobacillus pentosus
KR100994987B1 (ko) 피부 진정 효과를 가지는 화장료 조성물
EP3946378A1 (fr) Sulfate de dextran dans les dermatoses inflammatoires
JP6381641B2 (ja) 皮膚における外部刺激応答の鎮静化剤又は鎮静化方法
WO2007132900A1 (ja) 皮膚保湿剤および皮膚炎治療剤
EP2988765A1 (fr) Procédé d'obtention d'un mélange d'oligosaccharides neutres extraits de graines de lin
KR20180124438A (ko) 아쿠아포린-3 발현촉진 및 항염증 효과를 나타내는 올리고 히알루론산 함유 화장료 조성물
WO2009010587A1 (fr) Utilisation d'au moins un extrait de parties aériennes de l'epilobe et/ou de l'onagre pour la préparation d'une composition destinée à restaurer la fonction barrière des tissus kératinisés ou des muqueuses.
EP2879657B1 (fr) Nouveaux composés activateurs de l'activité enzymatique de sirt1 et compositions pharmaceutiques ou cosmétiques les comprenant
WO2020109445A1 (fr) Fucanes sulfates de bas poids moleculaire dans le traitement de la dermatite atopique
KR102334349B1 (ko) 자일로올리고당을 유효성분으로 함유하는 피부자극완화용 화장료 조성물
WO2022045261A1 (ja) Ｃｄ３９遺伝子の発現低下の抑制剤
EP2714705B1 (fr) Sucroses octasulfates de magnesium, leur preparation et leurs applications pharmaceutiques et cosmetiques
EP3522895B1 (fr) Utilisation de 6-o-(c8-c20 alkyl ester) de 1-o-(c1-c6 alkyl)-ss-d-glucoside comme agent de régénération et/ou de réparation cellulaire de l'épiderme
WO2021209593A1 (fr) Principe actif comprenant un extrait d'écorce de fruit immature de punica granatum et utilisations pour prevenir et/ou lutter contre l'acne
EP2714706A1 (fr) Sucroses octasulfates de calcium, leur préparation et leurs applications pharmaceutiques et cosmétiques
WO2019063929A1 (fr) Utilisation cosmetique de cellules meristematiques de syringa vulgaris l. pour une action apaisante et/ou adoucissante sur la peau
FR3123657A1 (fr) Hydrolysat protéique issu de baies de sorbier, composition cosmétique contenant un tel hydrolysat et utilisation pour le maintien de l’hydratation cutanée
JP2021070661A (ja) Ｔｓｌｐ遺伝子発現抑制用、ｉｌ−３３遺伝子発現抑制用、又はフィラグリン産生促進用組成物
FR2984740A1 (fr) Utilisation d'un extrait de ravenala en tant qu'ingredient actif cosmetique anti-age
FR2989278A1 (fr) Utilisation d'un extrait de ficoide glaciale pour le soin des peaux sensibles et/ou reactives

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211027

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220524